Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Strychnine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.98 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.98 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.70 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.65 |
| ▸ | GLRA1 | P23415 | 13/20 | 0.98 |
| ▸ | GLRB | P48167 | 13/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.98 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.98 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Strychnine SCHEMBL31047368 | 1.00 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29362678 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL93798 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14047653 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL29352583 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL12549549 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14117483 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL14029424 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL21985190 | 0.99 | GLRA1 (1.00) | GLRA1GLRBCYP3A4MEN1KMT2A | |
| Strychnine SCHEMBL25300604 | 0.98 | GLRA1 (0.98) | GLRA1GLRBCYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110849988-B | Method for detecting 33 alkaloids in honey | 徐敦明 | 2022-08-16 | — | — | CN | claimed |
| CN-110849988-A | Method for detecting 33 alkaloids in honey | 徐敦明 | 2020-02-28 | — | — | CN | claimed |
| CN-104072505-A | Method for extracting brucine and strychnine simultaneously | NANJING ZELANG MEDICAL TECH CO | 2014-10-01 | — | — | CN | claimed |
| CN-101838273-B | Method for extracting strychnine from semen strychni | UNIV XIANGTAN | 2012-03-28 | — | — | CN | claimed |
| CN-101838273-A | Method for extracting strychnine from semen strychni | UNIV XIANGTAN | 2010-09-22 | — | — | CN | claimed |
| US-20260083826-A1 | NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2026-03-26 | — | — | US | disclosed |
| WO-2024058196-A9 | NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025026292-A1 | 4-MEMBERED CYCLIC AMIDE COMPOUND AND USE THEREOF | 青岛清原化合物有限公司 | 2025-02-06 | — | — | WO | disclosed |
| WO-2024058196-A1 | NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2024-03-21 | — | — | WO | disclosed |
| WO-2023100949-A1 | PROTEOMICS-BASED RECEPTOR-LIGAND MATCHING FOR OPTIMIZING STEM CELL REPROGRAMMING | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2023-06-08 | — | — | WO | disclosed |
| CN-109661471-B | Promoter and use thereof | 索邦大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-115531480-A | Gel preparation for treating diabetic skin ulcer and preparation method thereof | 重庆伊士腾生物科技有限公司 | 2022-12-30 | — | — | CN | disclosed |
| EP-1139793-A2 | INHIBITORS OF THE BITTER TASTE RESPONSE | Mount Sinai School of Medicine of New York University (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6100046-A | CONTACTING TEST CELLS TRANSFORMED WITH AND EXPRESS NUCLEIC ACID ENCODING ALPHA9 SUBUNIT WITH A TEST COMPOUND, CONTACTING CONTROL CELLS WITH COMPOUND, IDENTIFYING COMPOUNDS THAT BIND TO SUBUNIT BY COMPARING AMOUNTS OF COMPOUND THAT BIND TO EACH | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2000-08-08 | — | — | US | disclosed |
| WO-2000038536-A2 | INHIBITORS OF THE BITTER TASTE RESPONSE | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2000-07-06 | — | — | WO | disclosed |
| US-6013766-A | NICOTINIC ACETYLCHOLINE RECEPTOR; FOR DEVELOPING TREATMENTS FOR MYASTHENIA GRAVIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE NICOTINE ADDICTION | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2000-01-11 | — | — | US | disclosed |
| US-5683912-A | DNA AND GENETIC ENGINEERING | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-11-04 | — | — | US | disclosed |
| EP-0765391-A1 | CLONING AND EXPRESSION OF AN ACETYLCHOLINE-GATED ION CHANNEL RECEPTOR SUBUNIT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1996003504-A1 | CLONING AND EXPRESSION OF AN ACETYLCHOLINE-GATED ION CHANNEL RECEPTOR SUBUNIT | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1996-02-08 | — | — | WO | disclosed |
| CN-87100769-A | Have 2-[2-[N, two (2-chloroethyl) the phosphinylidyne diamino oxygen bases of N-] ethyl] novel heterocyclic compound of group | — | 1987-09-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083826-A1 | NEW SYNTHETIC DRUGS FOR TREATING ALZHEIMER'S DISEASE | MAPT, DNM1L, APP | SCN1A 1912/4885SCN2A 3355/4885SCN3A 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.